Latest Updates

To be held in Bangalore from September 25 to 27, 2014

EBITDA for Q2CY14 stood at Rs 414 million

Suven Life Sciences achieved a PAT of Rs.34.73 crores for first quarter of 2014-15, an increase of 16.68 per cent compared to same…

LCZ696 significantly reduces cardiovascular deaths in head to head study against enalapril, in addition to current best treatment,…

Plans to launch in the US market in first quarter of 2015

GSK's experimental vaccine has already produced promising results in animal studies

Sales grew by 40 per cent

Awarded for their innovative approach to antibody-drug conjugates that may fight cancer

Recognised for ‘Cervical Cancer Screening Programme’

Continues to expand India footprint